Immunotherapy for malignant melanoma: a review and update.
Several different approaches to the application of specific active immunotherapy for the adjuvant therapy of melanoma have developed independently. Specific active immunotherapy refers to autologous or allogenic inoculation or transplantation of tumor cells or cell products into patients with cancer. Several different types of tumor vaccines have been studied and have been combined with different immunotherapeutic modalities. This report will include a review of several of those different techniques and will also review the observed 5-year survival rates for a melanoma tumor homogenate (concentrated) vaccine, developed by L.J. Humphrey and colleagues.
Department of Surgery, University of Oklahoma College of Medicine, Tulsa 74129.
J M
JM
McGee
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D006801:Humans; D016233:Immunotherapy, Active; D008545:Melanoma / Q000628:therapy*; D014612:Vaccines
D000276:Adjuvants, Immunologic; D014612:Vaccines